Early menopause: understanding ovarian insufficiency before 40

You are 34, your periods have been getting further apart for months, you feel hot at night, and you are told that "it is stress". Then one day a blood test lands: your ovaries no longer work as they did. The shock is twofold: the announcement itself, and the sense of being out of step. Menopause, in the collective imagination, arrives at 50. Not now.

This situation has a name: premature ovarian insufficiency (POI), or early menopause. It is poorly known, often diagnosed late, and yet it responds very well to care, provided you know what you are looking for. Here is what science says today, without dramatizing or minimizing.

What is premature ovarian insufficiency?

POI means the loss of ovarian function before the age of 40. In practice, the ovaries no longer release eggs regularly and produce far less estrogen. The body then finds itself in a hormonal state close to that of menopause, but years, sometimes decades, too early.

The word "insufficiency" was preferred to "early menopause" by the professional societies for an important reason: unlike classic menopause, ovarian function is not always completely and permanently switched off. It can fluctuate. That is a nuance with very concrete consequences, notably for contraception.^{1, 2}

A distinction is also drawn between premature menopause (before 40) and early menopause (between 40 and 45), which is less rare and whose long-term consequences are real, but generally less marked.

One point of vocabulary, because it comes up in the documents you will read: in the patient information sheet published in 2025 by the Societe Francaise de Menopause and GEMVi, the term premature ovarian insufficiency is reserved for a stop occurring before 40, while the expression early or advanced menopause there refers to the 40 to 45 band. Both words circulate; that is where the line is drawn.

How often?

The figure long repeated was "1 woman in 100". An international meta-analysis covering several dozen studies nonetheless arrived at a clearly higher pooled prevalence, around 3.7% of women (95% confidence interval: 3.1 to 4.3%), with higher rates in countries with a medium or low human development index.³

Let us be honest about what that figure is worth: it pools studies with heterogeneous methods and definitions, and the real range depends heavily on the population studied. What matters above all is the order of magnitude: POI is not an extremely rare medical curiosity. Depending on the estimates, it affects between one woman in 100 and one woman in 30.

How is the diagnosis made?

The international criteria are clear and rest on two elements that must both be present:^{1, 2}

• Periods absent or very irregular for at least 4 months (amenorrhea or oligomenorrhea);
• A high FSH level (follicle-stimulating hormone), above 25 IU/L.

On this point, the rule changed in 2024. The previous guideline, published in 2016, required a second FSH measurement four weeks apart.² The 2024 international guideline, co-signed by the European, American and international societies, now holds that a single measurement above 25 IU/L is enough when it goes with the cycle disturbance. A repeat at four or six weeks is requested only if the picture remains doubtful.¹

In practice, this means a single blood test can be enough to make the diagnosis, and that waiting for a second result must no longer delay care. If a professional tells you the measurement has to be repeated anyway before discussing anything, this 2024 guideline is the argument to put to them.

Looking for the cause, without expecting always to find it

In a large share of cases, the work-up finds no explanation: this is called idiopathic POI. It is frustrating, but it is the statistical reality. The most frequent identifiable causes are:

• Genetic: abnormalities of the X chromosome (Turner syndrome), premutation of the FMR1 gene (fragile X), hence the value of a karyotype and a search for a premutation;
• Autoimmune: associated notably with thyroid or adrenal involvement;
• Iatrogenic: chemotherapy, pelvic radiotherapy, bilateral ovarian surgery;
• Familial: a history in the mother or a sister raises the risk.

The international guidelines advise, at a minimum, a karyotype, a search for an FMR1 premutation, a measurement of adrenal antibodies and a thyroid work-up.^{1, 2}

Why it matters for your long-term health

This is the most important part of this article, and the one that makes it unacceptable to leave POI unmanaged. The problem is not only the discomfort of hot flashes: it is exposure to an estrogen deficit for ten, fifteen or twenty years longer than other women.

The heart and the vessels

A meta-analysis compared women with POI to those who reached menopause between 50 and 54: after adjustment for hormone therapy, the combined risk of cardiovascular events and coronary disease was roughly 1.3 to 1.4 times higher.⁴ Another systematic review, covering more than 900,000 participants from 20 cohorts, finds in women with early menopause a raised risk of type 2 diabetes, hyperlipidemia, coronary disease and overall cardiovascular events, compared with menopause after 45.⁵

These are observational data: they show a solid association, consistent from one study to another, but do not on their own prove the mechanism. They are nonetheless amply enough to justify heightened cardiovascular vigilance: blood pressure, lipid panel, blood sugar, smoking, physical activity.

The bones

Estrogen slows bone breakdown. Its early fall eats into bone capital at an age when it should still be protected. A 23-year longitudinal analysis showed that women with POI or early menopause had a higher prevalence and risk of osteoporosis and fracture than women who reached menopause at the usual age. A key point: hormone therapy was protective.⁶

A bone density scan at the time of diagnosis is therefore fully warranted, along with a sufficient intake of calcium and vitamin D and weight-bearing exercise. GEMVi recommends it systematically in the initial work-up of premature ovarian insufficiency, and notes that in France the test is reimbursed when menopause occurs before 40. That is a concrete argument to offer if you are told it is not necessary.

The brain

A meta-analysis of observational studies linked early menopause and POI to a raised risk of dementia.⁷ Caution in interpretation: the level of evidence remains moderate, findings in the literature are sometimes contradictory, and causation is not established. This is no announced fate: it is one more argument in favor of hormonal care and a protective lifestyle.

Mood

The psychological impact is real and frequently underestimated. A systematic review with meta-analysis finds in the women concerned a significantly raised risk of depression and anxiety, as well as poorer quality of life.⁸ This is neither fragility nor exaggeration: it is a documented consequence of a diagnosis that touches fertility, identity and the body, often at an age when those around you do not understand.

Hormone therapy: a different trade-off from after 50

This is a very widespread confusion, and it deprives many women of a treatment that would benefit them. The debates about the risks of menopause hormone therapy concern women who take hormones on top of what their body should naturally produce at their age.

In POI, the logic is reversed: the aim is to replace what the body should have made. The international guidelines are therefore in favor of hormone therapy, barring a contraindication, and propose continuing it at least until the usual age of menopause.^{1, 2} GEMVi places that age between 50 and 52, and applies the same rule when the loss of ovarian function follows preventive removal of the ovaries.

This treatment relieves vasomotor symptoms, protects bone and contributes to cardiovascular and urogenital health. The details (transdermal or oral route, dose, added progestogen if you have a uterus) are discussed with a doctor used to these situations, ideally a gynecologist or an endocrinologist.

The doses are not those of a treatment after 50. GEMVi notes that they are often higher, on the order of 2 mg of oral estradiol, a 50 microgram patch, or two to three pumps of gel a day. The goal is not to take the edge off symptoms, it is to restore hormone levels close to those of your age. If you are offered the smallest available dose from the outset, the question is worth asking.

If you still have your uterus, estrogen is never given alone. It must always be combined with progesterone, natural for preference or a close derivative, to reduce the risk of endometrial cancer. This is a constant rule of the French guidelines.

There are contraindications, even at this age. They are exceptional, but real: a history of breast cancer rules out hormone therapy. That is why this prescription is discussed, and is not decided on a forum.

An often forgotten point: contraception

Spontaneous ovulation remains possible with POI, and pregnancies do happen: GEMVi mentions a transient return of ovarian function in about 5 to 6% of women, and a spontaneous pregnancy in fewer than 5% of cases. It is rare, it is not zero, and it is unpredictable. Standard hormone replacement therapy is not a contraceptive. If you do not want a pregnancy, this subject must be raised explicitly. Conversely, if you are planning a pregnancy, it deserves a specialist consultation in fertility preservation or egg donation depending on the situation.

What you can do, concretely

• Know that a single FSH measurement has been enough since 2024: the second check at four or six weeks is required only if the picture remains doubtful. Do not let that wait delay your care.
• Ask for a work-up of the cause: karyotype, FMR1 premutation, adrenal antibodies, thyroid work-up.
• Get a baseline bone density scan at the time of diagnosis, then follow-up according to the results.
• Discuss hormone therapy with an informed doctor, without assuming it is "risky": the reasoning is not that of menopause at 52.
• Keep an eye on the heart: blood pressure, cholesterol, blood sugar, smoking. This follow-up should start early.
• Do not stay alone with the emotional side. Psychological support or a peer group is not an admission of weakness; it is a proportionate answer to a hard diagnosis.

In short

Premature ovarian insufficiency is neither rare nor simply "menopause ahead of schedule". It is a specific medical situation, calling for a rigorous diagnosis, a search for the cause, and above all hormonal care that too many women are refused through a mistaken application of guidelines meant for women of 50 and over.

If you recognize yourself in these lines (periods spaced out or absent before 40, hot flashes, sleep problems, vaginal dryness, difficulty conceiving), speak up. A blood test is enough to open the door.

⚠️ This article is provided for informational and educational purposes only. It does not replace medical advice, diagnosis or treatment. Always consult your doctor or a qualified health professional with any questions about your health.

How we work: our editorial method · Written and verified by Bouchra, editorial lead.